US-based Micron Biomedical has received $23.6m in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines.
The vaccine, which is virtually painless to administer, works by applying the microarray technology to the skin and then pressing a button for delivery.
This technology cuts down cold chain requirements and permits community health workers to inoculate children in minutes. It could boost treatment and vaccine access in low and middle-income countries.
Micron is also developing a needle-free measles-rubella (MR) vaccine leveraging its microarray technology.
The vaccine is intended for children from nine months old, subject to regulatory approvals and further clinical trials.
The funding will aid in developing a manufacturing plant, which will facilitate commercialising a first-ever MR vaccine based on microarray technology.
Micron Biomedical CEO Steven Damon stated: “We’re grateful to the Bill & Melinda Gates Foundation for the grant that allows us to build on our collaborative track record of bringing effective and life-saving vaccines to children and adults in communities with limited infrastructure.
“By supporting Micron’s efforts to develop a state-of-the-art, high-quality and large-scale production facility to manufacture our microarray technology, we have an opportunity to greatly improve on access and availability of measles/rubella vaccines, as well as other traditionally injectable global health vaccines, in underserved populations around the world.”
In May 2023, Micron reported positive data from its Phase I/II trial analysing the MR vaccine delivered via the company’s microarray technology.
The trial evaluated the immunogenicity, acceptability and safety of the injection-free vaccine in adults, toddlers and infants aged nine months and above.
Source: pharmaceutical-technology.com
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
